Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cybin Inc (NY: CYBN ) 8.840 -0.060 (-0.67%) Official Closing Price Updated: 8:00 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cybin Inc < Previous 1 2 ... 5 6 7 8 9 10 11 12 13 ... 38 39 Next > Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor June 27, 2023 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Psychedelic Science 2023 Conference June 21, 2023 Via Investor Brand Network Cybin to Participate in the 2023 MAPS Psychedelic Science Conference June 21, 2023 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Upcoming H.C. Wainwright Neuropsychiatry Conference June 15, 2023 Via Investor Brand Network InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Report on Status of Capital, Product Development June 08, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Cybin Inc. Provides Corporate Update June 08, 2023 From Cybin Inc. Via Business Wire Stocks That Hit 52-Week Lows On Tuesday June 06, 2023 On Tuesday, 69 stocks hit new 52-week lows. Via Benzinga Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More June 06, 2023 Major Investor Commits $30 Million To Psychedelics Funding Via Benzinga InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Changes in Scientific Management Team June 05, 2023 Via Investor Brand Network Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones June 05, 2023 From Cybin Inc. Via Business Wire May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances June 01, 2023 Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May. Via Talk Markets InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Jefferies Healthcare Conference June 01, 2023 Via Investor Brand Network Cybin to Present at the Jefferies Healthcare Conference June 01, 2023 From Cybin Inc. Via Business Wire Major Investor Commits $30M To Psychedelics Funding May 31, 2023 Canadian psychedelics biotech Cybin Inc. (NYSE: CYBN) entered into a common share purchase agreement with institutional investor Lincoln Park Capital Fund (LPC) for the sale of up to $30... Via Benzinga Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More May 31, 2023 Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... Via Benzinga InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Common Stock Purchase Agreement Totaling $30M May 31, 2023 Via Investor Brand Network Topics Derivatives Exposures Derivatives Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund May 30, 2023 From Cybin Inc. Via Business Wire Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes May 24, 2023 Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing Via Benzinga InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial May 24, 2023 Via Investor Brand Network Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial May 24, 2023 From Cybin Inc. Via Business Wire Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More May 15, 2023 Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... Via Benzinga Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released May 09, 2023 Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug... Via Benzinga PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Doses Last Subject in Phase 1, Part B CYB004-E Trial May 09, 2023 Via Investor Brand Network Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial May 09, 2023 From Cybin Inc. Via Business Wire April Psychedelic Drug Stocks Recap: The Ups And Downs April 30, 2023 Via Talk Markets InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate at Upcoming Milken Institute Global Conference April 28, 2023 Via Investor Brand Network Cybin to Participate at the 26th Annual Milken Institute Global Conference April 28, 2023 From Cybin Inc. Via Business Wire Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today April 21, 2023 Via Benzinga Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today April 20, 2023 Via Benzinga Cybin, Mind Medicine Among Top Psychedelic Movers Of Today April 19, 2023 Via Benzinga < Previous 1 2 ... 5 6 7 8 9 10 11 12 13 ... 38 39 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.